Searching for rational anti-N-methyl-D-aspartate treatment for depression: Reply [6]

Archives of General Psychiatry

Volumn 64, Issue 9, 2007, Pages 1100-1101

  Zarate Jr , Carlos A ^a   Charney, Dennis S ^b   Manji, Husseini K ^b  

^a CRC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; DIZOCILPINE; ELIPRODIL; IMIPRAMINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; RO 63 1908; UNCLASSIFIED DRUG;

CELL VACUOLE; COGNITION; COGNITIVE DEFECT; DEPRESSION; DISSOCIATIVE DISORDER; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; GLUCOSE METABOLISM; HUMAN; LEARNING; LETTER; LOW DRUG DOSE; MEMORY; NEUROTOXICITY; NONHUMAN; PSYCHOSIS;

EID: 34548384751     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.64.9.1100     Document Type: Letter

References (10)

1. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989;244(4910):1360-1362.
2. Hargreaves RJ, Hill RG, Iversen LL. Neuroprotective NMDA antagonists: the controversy over their potential for adverse effects on cortical neuronal morphology. Acta Neurochir Suppl (Wien). 1994;60:15-19.
3. Gill R, Alanine A, Bourson A, Buttelmann B, Fischer G, Heitz MP, Kew JN, Levet-Trafit B, Lorez HP, Malherbe P, Miss MT, Mutel V, Pinard E, Roever S, Schmitt M, Trube G, Wybrecht R, Wyler R, Kemp JA. Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl- benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther. 2002;302(3):940-948.
4. Visser E, Schug SA. The role of ketamine in pain management. Biomed Pharmacother. 2006;60(7):341-348.
5. Cho HS, D'Souza DC, Gueorguieva R, Perry EB, Madonick S, Karper LP, Abi-Dargham A, Belger A, Abi-Saab W, Lipschitz D, Bennet A, Seibyl JP, Krystal JH. Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine. Psychopharmacology (Berl). 2005;179(1):136-143.
6. Higgins GA, Ballard TM, Huwyler J, Kemp JA, Gill R. Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: evidence for an involvement of NR2B NMDA receptors in response inhibition. Neuropharmacology. 2003;44(3):324-341.
7. Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology (Berl). 2006;188(4):408-424.
8. Zajaczkowski W, Hetman M, Nikolaev E, Quack G, Danysz W, Kaczmarek L. Behavioural evaluation of long-term neurotoxic effects of NMDA receptor antagonists. Neurotox Res. 2000;1(4):299-310.
9. Guscott MR, Clarke HF, Murray F, Grimwood S, Bristow LJ, Hutson PH. The effect of (+/-)-CP-101,606, an NMDA receptor NR2B subunit selective antagonist, in the Morris watermaze. Eur J Pharmacol. 2003;476(3):193-199.
10. Maeng S, Zarate CA Jr, Du J, Schloesser R, McCammon J, Chen G, Manji HK. Cellular mechanism underlying the antidepressant effects of ketamine: role of AMPA receptors. Biol Psychiatry. In press.